Novo and existing backer GV participated in a round that lifted the heart disease drug developer's overall funding to more than $215m.
US-based cardiovascular disease drug developer Verve Therapeutics closed a $94m series B round yesterday featuring pharmaceutical firm Novo and GV, a corporate venturing subsidiary of internet and technology group Alphabet.
Wellington Management and Casdin Capital co-led the round, which included Redmile Group, Janus Henderson Investors, Cormorant Asset Management, Rock Springs Capital, Logos Capital, Surveyor Capital, RA Capital Management, Biomatics Capital and an unnamed healthcare-focused fund.
Verve is working on gene-editing therapies to treat cardiovascular disease. Its lead product candidate, VERVE-101,…
